Brevan Howard Capital Management LP Makes New Investment in Bausch + Lomb Co. (NYSE:BLCO)

Brevan Howard Capital Management LP bought a new stake in shares of Bausch + Lomb Co. (NYSE:BLCO - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 300,000 shares of the company's stock, valued at approximately $5,385,000. Brevan Howard Capital Management LP owned about 0.09% of Bausch + Lomb at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in BLCO. Barclays PLC bought a new position in Bausch + Lomb during the 3rd quarter worth $5,797,000. FNY Investment Advisers LLC acquired a new stake in shares of Bausch + Lomb in the 4th quarter worth about $72,000. Ellsworth Advisors LLC bought a new stake in Bausch + Lomb in the 4th quarter valued at about $665,000. Blue Trust Inc. boosted its stake in Bausch + Lomb by 68.3% during the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock valued at $48,000 after purchasing an additional 1,004 shares during the period. Finally, Renaissance Capital LLC grew its position in Bausch + Lomb by 116.2% in the 4th quarter. Renaissance Capital LLC now owns 94,182 shares of the company's stock worth $1,701,000 after purchasing an additional 50,622 shares during the last quarter. 11.07% of the stock is currently owned by institutional investors and hedge funds.

Bausch + Lomb Price Performance

Shares of NYSE BLCO traded up $0.47 during mid-day trading on Wednesday, reaching $11.37. The company had a trading volume of 611,863 shares, compared to its average volume of 650,238. The company has a 50-day moving average price of $13.63 and a two-hundred day moving average price of $16.72. The stock has a market cap of $4.02 billion, a PE ratio of -12.49, a P/E/G ratio of 0.85 and a beta of 0.58. The company has a current ratio of 1.60, a quick ratio of 1.01 and a debt-to-equity ratio of 0.72. Bausch + Lomb Co. has a 1-year low of $10.45 and a 1-year high of $21.69.

Bausch + Lomb (NYSE:BLCO - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The company reported ($0.07) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.10). Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The company had revenue of $1.15 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same quarter in the previous year, the firm posted $0.07 EPS. Bausch + Lomb's quarterly revenue was up 3.5% on a year-over-year basis. On average, equities analysts anticipate that Bausch + Lomb Co. will post 0.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BLCO has been the subject of several analyst reports. Needham & Company LLC reiterated a "hold" rating on shares of Bausch + Lomb in a research report on Thursday, April 24th. Stifel Nicolaus decreased their price target on Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating for the company in a research note on Thursday, April 3rd. Bank of America cut their price objective on shares of Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating on the stock in a research note on Thursday, February 20th. Morgan Stanley decreased their target price on shares of Bausch + Lomb from $18.00 to $12.00 and set an "equal weight" rating for the company in a research report on Tuesday. Finally, Evercore ISI dropped their price target on shares of Bausch + Lomb from $19.00 to $15.50 and set an "outperform" rating on the stock in a research report on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $15.50.

Bausch + Lomb Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.